<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991313</url>
  </required_header>
  <id_info>
    <org_study_id>LME-167</org_study_id>
    <nct_id>NCT02991313</nct_id>
  </id_info>
  <brief_title>Evaluation of a Multi-electrode Linear Type Catheter (D-1368-01-SI)</brief_title>
  <official_title>Evaluation of a Multi-electrode Linear Type Catheter (D-1368-01-SI) for Endocardial Ablation of Patients With Persistent Atrial Fibrillation (LME-167)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess acute safety and performance of the Multi-electrode
      Linear Type Catheter in conjunction with generator software V2.4.0 or above when used for the
      treatment of Persistent Atrial Fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Onset of Primary Adverse Events</measure>
    <time_frame>Within 7 days</time_frame>
    <description>Incidence of early onset (within 7 days of ablation procedure) primary Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmation of entrance block</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Acute procedural success defined as: Confirmation of entrance block in all targeted PVs after adenosine and /or isoproterenol challenge (taking into account a 30 minute waiting period from the last RF application at a PV target before verification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmation of bi-directional block</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Acute procedural success defined as: Confirmation of bi-directional block in all linear lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Device Effects (SADEs)</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of Serious Adverse Device Effects (SADEs) during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented Atrial Fibrillation/Atrial Flutter/Atrial Tachycardia</measure>
    <time_frame>3, 6 and 12 months post-procedure</time_frame>
    <description>Freedom from documented Atrial Fibrillation/Atrial Flutter/Atrial Tachycardia recurrence at 3, 6 and 12 months post-procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Endocardial Ablation Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ablation with Linear type catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endocardial Ablation Procedure</intervention_name>
    <arm_group_label>Endocardial Ablation Procedure</arm_group_label>
    <other_name>Linear Type Catheter (D-1368-01-SI)</other_name>
    <other_name>nMARQ TM Multi-channel RF generator (D-1341-07) with Software V2.4.0 or above</other_name>
    <other_name>Linear Ablation Connection Cable (M-5948-01-I)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years.

          2. Signed the Patient Informed Consent Form (ICF)

          3. Documented ongoing or previous symptomatic persistent AF (by physician's note
             indicating continuous AF ≥ 7 days)

          4. Failed at least one antiarrhythmic drug (AAD) (class I or III) as evidenced by
             recurrent symptomatic AF, or intolerable to the AAD.

          5. Able and willing to comply with all pre-, post-, and follow-up testing and
             requirements.

        Exclusion Criteria:

          1. Previous surgical or catheter ablation for atrial fibrillation

          2. Current condition of continuous AF &gt; 12 months (1 year) (Longstanding Persistent AF)
             or previously diagnosed as having Longstanding Persistent AF

          3. Any carotid stenting or endarterectomy

          4. Known with Cardioversion refractory history (the inability to restore sinus rhythm for
             30 secs or longer following electrical cardioversion.

          5. LA size &gt; 55 mm

          6. LVEF &lt;40%

          7. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac
             cause

          8. Significant pulmonary disease (i.e. restrictive pulmonary disease, constrictive or
             chronic obstructive pulmonary disease) or any other disease or malfunction of the
             lungs or respiratory system that produces chronic symptoms

          9. Uncontrolled heart failure or NYHA function class III and IV

         10. MI within the past 2 months

         11. Any cardiac surgery (i.e. CABG) within the past 2 months

         12. Subjects that have ever undergone valvular cardiac surgical/ percutaneous procedure
             (ie, ventriculotomy, atriotomy, and valve repair or replacement and presence of a
             prosthetic valve)

         13. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months

         14. Documented thromboembolic event (including TIA) within the past 12 months

         15. Significant congenital anomaly or medical problem that in the opinion of the
             investigator would preclude enrollment in this study

         16. Active illness or active systemic infection or sepsis

         17. Unstable angina

         18. History of blood clotting or bleeding abnormalities

         19. Contraindication to anticoagulation (eg, heparin or warfarin)

         20. Life expectancy less than 12 months

         21. Presence of intracardiac thrombus, myxoma, interatrial baffle or patch, tumor or other
             abnormality that precludes catheter introduction or manipulation

         22. Presence of a condition that precludes vascular access

         23. Women of child bearing potential whom are pregnant, lactating, or planning to become
             pregnant during the course of the clinical investigation

         24. Currently enrolled in another device, biologics, or drug study

         25. Contraindication for use of the investigational devices , as indicated in the
             respective Instructions For Use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmen Rousseeuw</last_name>
    <email>croussee@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Generale Regionale &quot;F. Miulli&quot;</name>
      <address>
        <city>Sant'Eramo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Grimaldi</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Grimaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Battista Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorenzo Gaïta</last_name>
    </contact>
    <investigator>
      <last_name>Fiorenzo Gaïta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghulam André Ng</last_name>
    </contact>
    <investigator>
      <last_name>Ghulam André Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital London</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark O'Neill</last_name>
    </contact>
    <investigator>
      <last_name>Mark O'Neill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

